Discovery of MDI-114215: A Potent and Selective LIMK Inhibitor To Treat Fragile X Syndrome
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c02694 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Alex G Baldwin und 23 weiteren Autor:innen. Beteiligte Einrichtung: Medicines Discovery Institute, School of Biosciences, Cardiff University, Main Building, Park Place, Cardiff CF10 3AT, U.K. Hauptthemen laut MEDLINE: Lim Kinases, Fragile X Syndrome, Protein Kinase Inhibitors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council.
Abstract (Originalsprache)
LIMKs are serine/threonine and tyrosine kinases responsible for controlling cytoskeletal dynamics as key regulators of actin stability, ensuring synaptic health through normal synaptic bouton structure and function. However, LIMK1 overactivation results in abnormal dendritic synaptic development that characterizes the pathogenesis of Fragile X Syndrome (FXS). As a result, the development of LIMK inhibitors represents an emerging disease-modifying therapeutic approach for FXS. We report the discovery of MDI-114215 (85), a novel, potent allosteric dual-LIMK1/2 inhibitor that demonstrates exquisite kinome selectivity. 85 reduces phospho-cofilin in mouse brain slices and rescues impaired hippocampal long-term potentiation in brain slices from FXS mice. We also show that LIMK inhibitors are effective in reducing phospho-cofilin levels in iPSC neurons derived from FXS patients, demonstrating 85 to be a potential therapeutic candidate for FXS that could have broad application to neurological disorders or cancers caused by LIMK1/2 overactivation and actin instability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medicines Discovery Institute, School of Biosciences, Cardiff University, Main Building, Park Place, Cardiff CF10 3AT, U.K.
- Centre for Medicines Discovery, University of Oxford, Roosevelt Drive, Oxford OX3 7DQ, U.K.
- Division of Neuroscience, School of Medicine, Medical Sciences Institute, Dundee University, Dow Street, Dundee DD1 5HL, U.K.
- The Neuro's Early Drug Discovery Unit (EDDU), Department of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, 3801 University Street, Montreal, Quebec H3A 2B4, Canada.
ORCID-Profile: Alex G Baldwin, Gui Jie Feng, Jonathan M Elkins, Simon E Ward
Förderung
- Medical Research Council
Zitieren
APA
Baldwin, A. G., Foley, D. W., Collins, R., Lee, H., Jones, D. H., Wahab, B., Waters, L., Pedder, J., Paine, M., Feng, G. J., Privitera, L., Ashall-Kelly, A., Thomas, C., Gillespie, J. A., Schino, L., Belelli, D., Rocha, C., Maussion, G., Krahn, A. I., …, & Ward, S. E. (2025). Discovery of MDI-114215: A Potent and Selective LIMK Inhibitor To Treat Fragile X Syndrome. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02694
Vancouver
Baldwin AG, Foley DW, Collins R, Lee H, Jones DH, Wahab B, et al. Discovery of MDI-114215: A Potent and Selective LIMK Inhibitor To Treat Fragile X Syndrome. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02694
BibTeX
@article{Baldwin2025,
author = {Baldwin, Alex G and Foley, David W and Collins, Ross and Lee, Hyunah and Jones, D Heulyn and Wahab, Ben and Waters, Loren and Pedder, Josephine and Paine, Marie and Feng, Gui Jie and Privitera, Lucia and Ashall-Kelly, Alexander and Thomas, Carys and Gillespie, Jason A and Schino, Lauramariú and Belelli, Delia and Rocha, Cecilia and Maussion, Gilles and Krahn, Andrea I and Durcan, Thomas M and Elkins, Jonathan M and Lambert, Jeremy J and Atack, John R and Ward, Simon E},
title = {Discovery of MDI-114215: A Potent and Selective LIMK Inhibitor To Treat Fragile X Syndrome},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c02694}
}
EUVIMED